pocketful logo light
pocketful logo light
Granules India Ltd logo

Granules India Ltd

NSE: GRANULES BSE: 532482

₹882.05

(2.62%)

Mon, 13 Jul 2026, 05:06 am

mtf coin illustrationMTF 5x

Granules India Share Price Live Chart

1 Day

(2.62%)

No Result Found

Summary

  • Market Cap (in Cr)

    19137.36

  • Net Profit (in Cr)

    501.52

  • P/B

    3.18

  • Sector P/E

    33.76

  • P/E

    23.55

  • EV/EBITDA

    12.81

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    14.45

  • ROCE

    15.61

  • Debt/Equity

    0.40

  • EPS (TTM)

    24.32

  • Dividend Yield

    0.23

  • Book Value

    205.21

  • Interest Cover

    7.39

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters38.0238.8238.8238.8238.84
FII15.3113.5514.0913.2415.15
DII17.0117.4817.9222.7422.45
Public29.6630.1529.1725.2023.57
Government00000

Read More

Technical Analysis

RSI

79.27

MACD

34.44

50 DMA

777.40

200 DMA

630.96

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic951.55870.35841.80789.15760.60707.95626.75
Fibonacci870.35839.33820.17789.15758.13738.97707.95
Camarilla835.58828.14820.69789.15805.81798.36790.92

Pivots Level: Classic

R3

+162.40

951.55

R2

+81.20

870.35

R1

+52.65

841.80

789.15
789.15
Pivot Point
LTP: 903.85

S1

-28.55

760.60

S2

-81.20

707.95

S3

-162.40

626.75

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    857.42

  • 20-EMA

    827.99

  • 30-EMA

    808.27

  • 50-EMA

    776.69

  • 100-EMA

    719.78

  • 200-EMA

    656.36

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 Apr 2026dividend₹1.75 Dividend /Share30 Jul 2026
29 Apr 2026agm
29 Apr 2026board-meetingsAccounts, Quarterly Results, Final Dividend
23 Jan 2026board-meetingsQuarterly Results
23 Dec 2025egm
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
01 Jul 2025dividendFinal Dividend - Rs. - 1.531 Jul 2025
28 May 2025agm
28 May 2025dividend₹1.50 Dividend /Share31 Jul 2025
30 Jun 2024dividendAnnual General Meeting/Dividend - Rs 1.50 Per Share31 Jul 2024

Read More

Peer Comparison

Granules India Ltd logo

Granules India Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

Granules India Ltd About

Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).(Source : 202503-Annual Report Page No:134)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1991

Headquarters

CEO

C Krishna Prasad

Employees

Contact

Website icon

Website

http://www.granulesindia.com

Email icon

Email

investorrelations@granulesindia.com; mail@granules

Phone icon

Phone

91-40-69043500

Location icon

Location

15th Floor Granules Tower, Botanical Garden Road Kondapur, Hyderabad, Telangana, 500084

Read More

Granules India Ltd Company History

YearHistory
2020
  • Granules India arm got USFDA nod for Valganciclovir hydrochloride oral solution.
  • Granules India received USFDA approval for Colchicine Tablets.
  • Granules Pharmaceuticals Inc. got USFDA nod for Colchicine tablets.
  • Granules India got tentative USFDA nod for Colchicine capsules for gout.
  • Granules India got tentative nod from USFDA for expectorant tablets.
2021
  • Granules got USFDA nod for diabetes management drug.
  • Granules India got USFDA nod for generic low blood potassium treatment capsules.
  • Granules India received USFDA approval for Acetaminophen, Aspirin and Caffeine Tablets.
  • Granules India received USFDA approval for Dofetilide capsules.
  • Granules India's US unit got two observations from USFDA.
2022
  • Granules India received licenses from MPP to market Nirmatrelvir and Ritonavir.
  • Granules Pharmaceuticals Inc. received ANDA approval for Bupropion Hydrochloride Extended-Release Tablets.
  • Granules Pharmaceuticals Inc. received ANDA approval for Potassium Chloride for Oral Solution USP, 20 mEq.
2023
  • Granules India received USFDA approval for Losartan Potassium Tablets.
  • Granules India forged a strategic partnership with Greenko ZeroC.
2024
  • Granules India Limited was honored with the Golden Peacock Award for Sustainability.
  • Granules India received approval from the US health regulator to market a generic medication to treat major depressive disorder.
  • The company received approval from the US Food & Drug Administration for Bupropion Hydrochloride extended-release tablets USP (SR) in strength of 100 mg, 150 mg, and 200 mg.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
L7 HITECH PRIVATE LIMITEDbulkBuy171737587.4114 Jan 2025
L7 HITECH PRIVATE LIMITEDbulkSell1546000577.8514 Jan 2025
FIDELITY INDIA FUNDblockSell199081596.0220 Dec 2024
EDELWEISS MUTUAL FUNDblockBuy33500059620 Dec 2024
KOTAK MAHINDRA LIFE INSURANCE COMPANY LIMITEDblockBuy30000059620 Dec 2024
PAULOMI KETANKUMAR DOSHIblockBuy738285596.120 Dec 2024
ITI MUTUAL FUNDblockBuy50374159620 Dec 2024
BANDHAN MUTUAL FUNDblockBuy28696359620 Dec 2024
SBI LIFE INSURANCE COMPANY LIMITEDblockBuy50000059620 Dec 2024
BANDHAN MUTUAL FUNDblockBuy28601159620 Dec 2024

Read More

Granules India Ltd News

Granules India: ₹16.49 Cr Block Trade on NSE

Granules India Ltd. recorded a block trade on NSE worth ₹16.49 crores, involving approximately 185,143 shares at a price of ₹890.90 per share.

09 Jul 2026

equity-markets

Granules India to hold Q1 FY27 earnings call

Granules India Limited will host an earnings call on July 21, 2026, to discuss Q1 FY27 results. Key executives will participate.

09 Jul 2026

companies

Granules India Wins Exclusive FTF ANDA Approval

Granules India secures exclusive First-To-File ANDA approval for Extended-Release Sodium Oxybate Oral Suspension, marking a significant regulatory milestone.

06 Jul 2026

companies

Granules India to host investor meet in London

Granules India Limited will hold an analyst and investor meeting in London on June 23 and 24, 2026. The company confirmed no unpublished price-sensitive information will be shared.

15 Jun 2026

companies

Granules Pharma Gets USFDA EIR for Chantilly Facility

Granules Pharmaceuticals, a subsidiary of Granules India, receives USFDA Establishment Inspection Report for its Chantilly facility, classified as Voluntary Action Indicated after inspection with four observations.

03 Jun 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number